Page 102 - GPD-4-1

Gene & Protein in Disease Oral-ERT in PD knockout mice with tobrhGAA

doi: 10.1002/ajmg.c.31319 doi: 10.1016/j.ymgme.2012.04.027
23. Joseph A, Munroe K, Housman M, Garman R, Richards S. 33. Wang J, Lozier J, Johnson G, et al. Neutralizing antibodies to
Immune tolerance induction to enzyme-replacement therapeutic enzymes: Considerations for testing, prevention
therapy by co-administration of short-term, low-dose and treatment. Nat Biotechnol. 2008;26:901-908.
methotrexate in a murine Pompe disease model. Clin Exp doi: 10.1038/nbt.1484
Immunol. 2013;152:138-146.
34. Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS.
doi: 10.1002/ajmg.c.31319
Elimination of antibodies to recombinant enzyme in
24. Banugaria SG, Prater SN, McGann JK, et al. Bortezomib Pompe’s disease. N Engl J Med. 2009;360:194-195.
in the rapid reduction of high sustained antibody titers in doi: 10.1056/NEJMc0806809
disorders treated with therapeutic protein: Lessons learned
from Pompe disease. Genet Med. 2013;15:123-131. 35. Hunley TE, Corzo D, Dudek M, et al. Nephrotic syndrome
complicating a-glucosidase replacement therapy for Pompe
doi: 10.1038/gim.2012.110
disease. Pediatrics. 2004;114:e532-e535.
25. Berrier KL, Kazi ZB, Prater SN, et al. CRIM-negative doi: 10.1542/peds.2003-0988-L
infantile Pompe disease: Characterization of immune
responses in patients treated with ERT monotherapy. Genet 36. Banugaria SG, Prater N, Patel TT, et al. Algorithm for the
Med. 2015;17:912-918. early diagnosis and treatment of patients with cross reactive
immunologic material-negative classic Infantile Pompe
doi: 10.1038/gim.2015.6
disease: A step towards improving the efficacy of ERT. PLoS
26. Banugaria SG, Prater SN, Ng YK, et al. The impact of One. 2013;8:e67052-12.
antibodies on clinical outcomes in diseases treated with 37. Nayak S, Doerfler PA, Porvasnik SL, et al. Immune
therapeutic protein: Lessons learned from infantile Pompe responses and hypercoagulation in ERT for Pompe disease
disease. Genet Med. 2011;13:729-736.
are mutation and rhGAA dose dependent. PLoS One.
doi: 10.1097/GIM.0b013e3182174703 2014;9:e98336.
27. Messinger YH, Mendelsohn NJ, Rhead W, et al. Successful doi: 10.1371/journal.pone.0098336
immune tolerance induction to enzyme replacement 38. de Vries JM, Kuperus E, Hoogeveen-Westerveld M, et al.
therapy in CRIM–negative infantile Pompe disease. Genet Pompe disease in adulthood: Effects of antibody formation
Med. 2012;14:135-142.
on enzyme replacement therapy. Genet Med. 2017;19:90-97.
doi: 10.1038/gim.2011.4
doi: 10.1038/gim.2016.70
28. Al Khallaf HH, Geffrard J, Botha E, Ali Pervaiz M. 39. Ohashi T, Iizuka S, Shimada Y, et al. Oral administration
CRIM-negative Pompe disease patients with satisfactory of recombinant human acid a-glucosidase reduces specific
clinical outcomes on enzyme replacement therapy. JIMD antibody formation against enzyme in mouse. Mol Genet
Rep. 2012;192:133-137.
Metab. 2011;103:98-100.
doi: 10.1007/8904_2012_192
40. Parini R, De Lorenzo P, Dardis A, et al. Long term clinical
29. Brooks DS. Immune response to enzyme replacement history of an Italian cohort of infantile onset Pompe disease
therapy in lysosomal storage disorder patients and animal treated with enzyme replacement therapy. Orphanet J Rare
models. Mol Genet Metab. 1999;68:268-275. Dis. 2018;13:32-44.
doi: 10.1006/mgme.1999.2894 doi: 10.1186/s13023-018-0771-0
30. Kishnani PS, Goldenberg PC, DeArmey SL, et al. Cross- 41. Gutschmidt K, Musumeci O, Díaz-Manera J, et al. STIG
reactive immunologic material status affects treatment study: Real-world data of long-term outcomes of adults with
outcomes in Pompe disease infants. Mol Genet Metab. Pompe disease under enzyme replacement therapy with
2010;99:26-33. alglucosidase alfa. J Neurol. 2021;268:2482-2492.
doi: 10.1016/j.ymgme.2009.08.003 doi: 10.1007/s00415-021-10409-9
31. de Vries JM, van der Beek N, Kroos MA, et al. High antibody 42. Korlimarla A, Spiridigliozzib GA, Stefanescua M,
titer in an adult with Pompe disease affects treatment with Austina SL, Kishnania PS. Behavioral, social and school
alglucosidase alfa. Mol Genet Metab. 2010;101:338-345. functioning in children with Pompe disease. Mol Genet
Metab Rep. 2020;25:100635.
doi: 10.1016/j.ymgme.2010.08.009
doi: 10.1016/j.ymgmr.2020.100635
32. Patel TT, Banugaria SG, Case LE, Wenninger S, Schoser B,
Kishnani PS. The impact of antibodies in late-onset Pompe 43. Raben N, Jatkar T, Lee A, et al. Glycogen stored in skeletal
disease: A case series and literature review. Mol Genet Metab. but not in cardiac muscle in acid a-glucosidase mutant
2012;106:301-309. (Pompe) mice is highly resistant to transgene-encoded

Volume 4 Issue 1 (2025) 16 doi: 10.36922/gpd.1760